Court Blocks Referendum on Arkansas Eye Surgery Law
The Arkansas Supreme Court on Thursday blocked a referendum on a law expanding the procedures optometrists can perform. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - September 18, 2020 Category: American Health Source Type: news

Walmart Health, the retailer's primary care service, is coming to Tampa
Walmart Inc. is planning to bring its primary care services to Tampa. The retail giant said Thursday that it is "beginning conversations" to bring Walmart Health to Orlando and Tampa. Walmart Health, which offers primary care services as well as dental care, optometry, counseling services and X-rays, is set to debut in Florida in Jacksonville with seven locations to open there in 2021. The company did not disclose any potential locations for Tampa. It has dozens of locations throughout the Tampa… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 17, 2020 Category: Pharmaceuticals Authors: Ashley Gurbal Kritzer Source Type: news

Does Wearing Glasses Protect You From Coronavirus?
After researchers noticed fewer nearsighted patients in a hospital ward in China, they speculated that wearing glasses might offer some protection against Covid-19. (Source: NYT Health)
Source: NYT Health - September 17, 2020 Category: Consumer Health News Authors: Tara Parker-Pope Tags: Eyes and Eyesight Eyeglasses Coronavirus (2019-nCoV) Face Protective Clothing and Gear Source Type: news

Do Ordinary Eyeglasses Offer Protection Against COVID-19?
Title: Do Ordinary Eyeglasses Offer Protection Against COVID-19?Category: Health NewsCreated: 9/16/2020 12:00:00 AMLast Editorial Review: 9/17/2020 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 17, 2020 Category: Opthalmology Source Type: news

Yousefi to develop artificial intelligence to improve glaucoma research, diagnosis
(University of Tennessee Health Science Center) Siamak Yousefi, Ph.D., an assistant professor in the Department of Ophthalmology and the Department of Genetics, Genomics, and Informatics at the University of Tennessee Health Science Center, has received two grants worth more than $600,000 combined to further develop artificial intelligence (AI) to help diagnose and monitor glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 17, 2020 Category: International Medicine & Public Health Source Type: news

Dr Reddy's Laboratories launches over-the-counter eye allergy drop in US
Dr Reddy's said Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 per cent and 0.1 per cent, are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Blindness and neurological sequelae following carbon monoxide poisoning: effective treatment with hyperbaric oxygen - Cardoso PC, La Fuente A, Subbotina N, Cargnel EG.
We present two patients who developed visual deterioration due to carbon monoxide poisoning. They were treated with hyperbaric oxygen and recovered not only their vision but also they improved neurological signs and symptoms. We believe that implementation... (Source: SafetyLit)
Source: SafetyLit - September 16, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Parkinson's Drug Eyed as Treatment for Severe Macular Degeneration
Title: Parkinson's Drug Eyed as Treatment for Severe Macular DegenerationCategory: Health NewsCreated: 9/16/2020 12:00:00 AMLast Editorial Review: 9/16/2020 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 16, 2020 Category: Opthalmology Source Type: news

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Media News - September 16, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Investor Update - September 16, 2020 Category: Pharmaceuticals Source Type: news

Same-Day Bilateral Cataract Surgery Increases During Pandemic Same-Day Bilateral Cataract Surgery Increases During Pandemic
Immediately sequential bilateral cataract surgery, or ISBCS, has become a more popular method for cataract surgery in recent years, and the pandemic dramatically increased interest in the approach, according to a group of eye surgeons.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 15, 2020 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Pediatric Ophthalmologists Hit Hard Financially by COVID-19
TUESDAY, Sept. 15, 2020 -- Pediatric ophthalmologists are financially struggling as a result of the COVID-19 pandemic, according to research recently published in the Journal of the American Association for Pediatric Ophthalmology and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news

What Can I Do to Prevent Glaucoma?
Title: What Can I Do to Prevent Glaucoma?Category: Diseases and ConditionsCreated: 9/11/2020 12:00:00 AMLast Editorial Review: 9/11/2020 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 11, 2020 Category: Opthalmology Source Type: news

Glaucoma: Causes, Symptoms, Types, and Treatment
Title: Glaucoma: Causes, Symptoms, Types, and TreatmentCategory: Diseases and ConditionsCreated: 9/11/2020 12:00:00 AMLast Editorial Review: 9/11/2020 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 11, 2020 Category: Opthalmology Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Media News - September 11, 2020 Category: Pharmaceuticals Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Investor Update - September 11, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Media News - September 10, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Investor Update - September 10, 2020 Category: Pharmaceuticals Source Type: news

Seeing the eye like never before
(University of Washington Health Sciences/UW Medicine) In a big step for ophthalmology, scientists created a method to view the inner workings of the eye and its diseases at the cellular level. Currently, researchers can only see a broad section of the retina. This new technology allows them to zoom into just one part of a cell. In their words, they have accelerated the process for vision restoration. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

LSU Health study 1st to show nonharmful stress protects against disease in offspring
(Louisiana State University Health Sciences Center) Research led by Jeff Gidday, PhD, Professor of Ophthalmology, Biochemistry, Neuroscience, and Physiology at LSU Health New Orleans School of Medicine, reports what is believed to be the first study in a mammalian model documenting the reprogramming of heritability to promote disease resilience in the next generation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 10, 2020 Category: Biology Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Media News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Investor Update - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients
Basel, 8 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) 510k clearance for the cobas ® BKV Test on the cobas® 6800 and 8800 Systems. The test was previously granted FDA Breakthrough Device designation demonstrating the improved treatment or diagnosis of life-threatening diseases or conditions for transplant patients. The test provides standardised, high-quality results that can he lp healthcare professionals better assess the risk of complications caused by the BK virus in transplant patients and identify effective treatment options. BK virus (BKV) is a m...
Source: Roche Investor Update - September 8, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients
Basel, 8 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) 510k clearance for the cobas ® BKV Test on the cobas® 6800 and 8800 Systems. The test was previously granted FDA Breakthrough Device designation demonstrating the improved treatment or diagnosis of life-threatening diseases or conditions for transplant patients. The test provides standardised, high-quality results that can he lp healthcare professionals better assess the risk of complications caused by the BK virus in transplant patients and identify effective treatment options. BK virus (BKV) is a m...
Source: Roche Media News - September 8, 2020 Category: Pharmaceuticals Source Type: news

Lumenis Announces NuEra(R) Tight with FocalRF(TM) Technology, a Breakthrough in Aesthetic Medical Devices, now available in Europe and the Middle East offering Personalized Body Sculpting Treatments
YOKNEAM, Israel, Sept. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, is proud to announce the revolutionary NuEra Tight with ... Devices, Dermatology, Product Launch Lumenis, NuEra Tight, FocalRF, Fat Reduction, Skin Tightening (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2020 Category: Pharmaceuticals Source Type: news

A new twist on DNA origami
(Arizona State University) A team* of scientists from ASU and Shanghai Jiao Tong University (SJTU) led by Hao Yan, ASU's Milton Glick Professor in the School of Molecular Sciences, and director of the ASU Biodesign Institute's Center for Molecular Design and Biomimetics, has just announced the creation of a new type of meta-DNA structures that will open up the fields of optoelectronics (including information storage and encryption) as well as synthetic biology. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 7, 2020 Category: Biology Source Type: news

Case report: projectile into right frontal lobe from a nail gun - Patchana T, Taka TM, Ghanchi H, Wiginton J, Wacker M.
We present a case of a nail gun injury penetrating the right maxillary sinus and frontal lobe with complaints of headache and right eye blindness. After surgical removal and treatment, there were no neurological deficits aside from the persistence of right... (Source: SafetyLit)
Source: SafetyLit - September 5, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

The dangers of police use of non-lethal weapons towards protesters: an ophthalmic perspective - Ahuja AS, Forouhi M.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - September 5, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Seven-year follow-up of a patient with a retained needlefish jaw fragment abutting against his left internal carotid artery - Daigle P, Mehta S, Bhayana R, Das S, Bharatha A, Nijhawan N.
A 51-year-old man presented to the ophthalmology service with binocular diplopia and facial numbness. The patient was returning from a trip to Mexico. He reported having been hit in the left periocular region by a fish while swimming. Local doctors repaire... (Source: SafetyLit)
Source: SafetyLit - September 4, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Dr. Allen Zieker focuses on patient care, and growth has followed
In his 36-year career, ophthalmologist Dr. Allen Zieker estimates he ’s performed more than 30,000 eye care operations. He now completes about 1,500 cataract surgeries annually, about 40 to 60 in a week. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 3, 2020 Category: Pharmaceuticals Authors: Justin Dawes Source Type: news

Cystadrops (Cysteamine Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 3, 2020 Category: Drugs & Pharmacology Source Type: news

Regulation of sleep homeostasis mediator adenosine by basal forebrain glutamatergic neurons
Sleep and wakefulness are homeostatically regulated by a variety of factors, including adenosine. However, how neural activity underlying the sleep-wake cycle controls adenosine release in the brain remains unclear. Using a newly developed genetically encoded adenosine sensor, we found an activity-dependent rapid increase in the concentration of extracellular adenosine in mouse basal forebrain (BF), a critical region controlling sleep and wakefulness. Although the activity of both BF cholinergic and glutamatergic neurons correlated with changes in the concentration of adenosine, optogenetic activation of these neurons at p...
Source: ScienceNOW - September 3, 2020 Category: Science Authors: Peng, W., Wu, Z., Song, K., Zhang, S., Li, Y., Xu, M. Tags: Neuroscience, Online Only r-articles Source Type: news

Radiation-Emitting Products
From medical X-ray scanners used to see inside the body to surgical lasers used for cosmetic purposes or to improve eyesight, FDA ensures the safety and effectiveness of a wide range or products that emit radiation. To learn more, read these Consumer Updates. (Source: FDA Consumer Health Information Updates)
Source: FDA Consumer Health Information Updates - September 2, 2020 Category: Consumer Health News Authors: FDA Source Type: news

Upneeq (Oxymetazoline Hydrochloride Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2020 Category: Drugs & Pharmacology Source Type: news

Cystadrops (Cysteamine Ophthalmic Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2020 Category: Drugs & Pharmacology Source Type: news

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS
Basel, 1 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas ® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.“Roche is committed to improving diagnostic technologies in the fight against HIV/AIDS,” said Thomas Schinecker, CEO Roche Diagnostics. “Being able to reliably determi...
Source: Roche Investor Update - September 1, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS
Basel, 1 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas ® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.“Roche is committed to improving diagnostic technologies in the fight against HIV/AIDS,” said Thomas Schinecker, CEO Roche Diagnostics. “Being able to reliably determi...
Source: Roche Media News - September 1, 2020 Category: Pharmaceuticals Source Type: news

In an Era of Face Masks, We ’re All a Little More Face Blind
Your brain ’s powers of facial recognition are going to need some time to get used to the coverings we’re wearing to keep each other healthy. (Source: NYT Health)
Source: NYT Health - September 1, 2020 Category: Consumer Health News Authors: Elizabeth Preston Tags: Face Masks Prosopagnosia (Brain Disorder) Psychology and Psychologists Eyes and Eyesight Senses and Sensation Emotions Research your-feed-science Source Type: news

Novel Solutions to Maintain Glaucoma Care During COVID-19 Novel Solutions to Maintain Glaucoma Care During COVID-19
In-person visits are fraught with concern, but virtual replacements won't cut it either. Dr Shuchi Patel looks at some potential alternatives.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2020 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Orbital firearm injuries - Mayer CS, Bohnacker S, Storr J, Klopfer M, Cordeiro SA, Khoramnia R.
We report on seven consecutive cases of patients ... (Source: SafetyLit)
Source: SafetyLit - August 31, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

My face blindness is embarrassing – but it tells me a lot about other people
I grew up thinking I just didn ’t fit it. Now, I immediately tell people I can’t recognise faces – and their response is a good measure of kindness versus egoSunday morning. I walk down to the beach with the dog straining at her lead. I ’m already on high alert. It’s the moment in the week when people are most likely to be wandering along the seafront, feeling chatty. I’m mentally priming myself, sorting through the categories I might encounter: parents from the schoolyard (hopefully with their children), people I’ve worked with (increasingly hopeless), neighbours from the surround...
Source: Guardian Unlimited Science - August 30, 2020 Category: Science Authors: Katherine May Tags: Life and style Psychology Science Health & wellbeing Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - August 28, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Media News - August 28, 2020 Category: Pharmaceuticals Source Type: news

LSU Health study explains multipronged SARS-CoV-2 attack and widespread COVID-19 infection
(Louisiana State University Health Sciences Center) A study of a gateway receptor for SARS-CoV-2 led by Walter J. Lukiw, PhD, Professor of Neuroscience, Neurology and Ophthalmology at LSU Health New Orleans' Neuroscience Center of Excellence and School of Medicine, may help explain the wide variety of symptoms and organs involved with SARS-CoV-2 infection and COVID-19. The results suggest that a multi-organ infection with SARS-CoV-2 may be via the angiotensin-converting enzyme 2 (ACE2) receptor, which is found almost everywhere throughout the body. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 28, 2020 Category: Infectious Diseases Source Type: news

IrisVision and Seva Foundation work to treat vision impairment; Iron Bow Technologies integrates with ViiMed; and more digital health deals
In a partnership announced this week, IrisVision and Seva Foundation plan to develop new technology to treat vision impairment and prevent blindness in underserved regions of the globe. Seva has agreed to provide IrisVision with a $200,000 grant to create the technology. (Source: mobihealthnews)
Source: mobihealthnews - August 27, 2020 Category: Information Technology Source Type: news

Pandemic Learning Can Strain Children's Eyes
THURSDAY, Aug. 27, 2020 -- If your child will be doing online learning this school year, you need to take steps to protect them from eye strain, the American Academy of Ophthalmology says. " I really have seen a marked increase in kids suffering... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 27, 2020 Category: General Medicine Source Type: news

Online Therapy, Booming During the Coronavirus Pandemic, May Be Here to Stay
Mental health flows from the ceramic jug psychotherapist Lori Gottlieb keeps on her desk. There’s nothing special about the jug—a minor accessory in an office designed with the sort of tidy impersonality common to her field. And there’s no special elixir in it—just water. But all the same, the jug provides a certain kind of healing. When patients are struggling, crying, overcome in some way, Gottlieb, a Los Angeles based practitioner and author of the book Maybe You Should Talk to someone, will offer up a cup of water, pour it for them and hand it across. In that small gesture is a whole constellati...
Source: TIME: Health - August 27, 2020 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news

FDA Approves Cystadrops (cysteamine) Ophthalmic Solution for the Ocular Manifestations of Cystinosis
LEBANON, N.J., Aug. 25, 2020 /PRNewswire/ -- Recordati Rare Diseases Inc., today announced the U.S. Food and Drug Administration (FDA) has approved Cystadrops (cysteamine ophthalmic solution) 0.37%. Cystadrops is a new, viscous eye drop solution... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 26, 2020 Category: Drugs & Pharmacology Source Type: news

Causes of childhood blindness and visual impairment in Ouagadougou: About 398 cases - Ahnoux-Zabsonre A, Meda R, Diallo JW, Djiguimde WP, Sanou J, Meda-Hien G, Sankara P, Diomand é A.
INTRODUCTION: Childhood blindness is a public health problem in developing countries. The goal of this study was to focus on the epidemiological and clinical patterns of moderate to severe, uni- or bilateral childhood blindness and severe visual impairment... (Source: SafetyLit)
Source: SafetyLit - August 26, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Delivering patient eye care services during and beyond COVID-19
The College of Optometrists and The Royal College of Ophthalmologists have developed a joint vision that sets out principles and recommendations for the development and governance of high quality eye care services that involve other key policy and commissioning organisations. (Source: NHS Networks)
Source: NHS Networks - August 26, 2020 Category: UK Health Source Type: news